Clinical Characteristics and Treatment Outcomes of Children with Primary Osteoporosis.
| Autor: | Çetin, Sirmen Kızılcan, Şıklar, Zeynep, Aycan, Zehra, Özsu, Elif, Ceran, Ayşegül, Şenyazar, Gizem, Karaca, Seda Erişen, Berberoğlu, Merih |
|---|---|
| Předmět: |
DRUG therapy
DIPHOSPHONATES BONE fracture prevention OSTEOPOROSIS prevention STATISTICS NONPARAMETRIC statistics CONFIDENCE intervals ACQUISITION of data RETROSPECTIVE studies OSTEOPOROSIS TREATMENT effectiveness T-test (Statistics) MEDICAL records DESCRIPTIVE statistics BONE density DATA analysis software DATA analysis SYMPTOMS EVALUATION CHILDREN |
| Zdroj: | Turkish Archives of Pediatrics; May2023, Vol. 58 Issue 3, p314-321, 8p |
| Abstrakt: | Objective: Primary osteoporosis is a rare and essential problem in childhood that can cause severe skeletal deformities. We aimed to reveal the spectrum of primary osteoporosis and assess the effectiveness and safety of bisphosphonates in increasing bone mineral density and reducing fractures. Materials and Methods: Patients with primary osteoporosis who received at least one course of pamidronate or zoledronic acid were included in the study. Patients were divided into 2 groups, osteogenesis imperfecta and non-osteogenesis imperfecta subjects. We evaluated bone densitometer parameters, activation scores, pain status, deformity status, and the number of fractures per year in all patients. Results: Of the 31 patients, 21 with osteogenesis imperfect, 3 patients with spondyloocular syndromes, 2 with Bruck Syndrome, and 5 with idiopathic juvenile osteoporosis were included. A total of 21 patients had received pamidronate treatment, while only 4 received zoledronic acid, and 6 of them switched from pamidronate to zoledronic acid. At the end of the treatment, the mean bone mineral density height-adjusted Z-score increased from −3.39 ± 1.30 to −0.95 ± 1.34. The number of fractures per year decreased from 2.28 ± 2.67 to 0.29 ± 0.69. The activation score increased from 2.81 ± 1.47 to 3.16 ± 1.48. The pain decreased significantly. There was no difference in bone mineral density increase in patients treated with pamidronate or zoledronic acid. Conclusion: Those with osteogenesis imperfecta were diagnosed at an earlier age with severe deformity and fractures. Pamidronate and zoledronic acid increased bone mineral density in all types of primary osteoporosis. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|